SCHEDULE 13D/A: Lipella Pharmaceuticals Insider Jonathan Kaufman Updates Beneficial Ownership to 8.0%
Beneficial Ownership Update
Jonathan H. Kaufman, President and CEO of Lipella Pharmaceuticals Inc., has filed an Amendment No. 12 to his Schedule 13D, updating his beneficial ownership in the company to 8.0% of outstanding common stock.
Summary
- Jonathan H. Kaufman, who serves as President, Chief Executive Officer, Secretary, Treasurer, and Chairman of the Board of Directors of Lipella Pharmaceuticals Inc., has updated his beneficial ownership in the company.
- As of the filing date, Mr. Kaufman beneficially owns an aggregate of 212,289 shares of Lipella Pharmaceuticals Inc. Common Stock.
- This ownership represents 8.0% of the company's total outstanding Common Stock, which stands at 2,548,811 shares as of the date of this Amendment No. 12.
- His beneficial ownership comprises 112,352 shares purchased with personal funds and 99,937 shares issuable upon the exercise of fully vested stock options awarded by the Issuer.
- This filing, Amendment No. 12, serves to update Mr. Kaufman's beneficial ownership percentage and does not modify other previously reported information in the Schedule 13D, except as specifically amended.
Sentiment
Score: 5
Explanation: The document is a factual update on beneficial ownership and does not contain information that would indicate a positive or negative sentiment regarding the company's performance or outlook.
Future Outlook
The document does not contain any forward-looking statements or guidance regarding the company's future operations or financial performance.
Industry Context
This filing is a routine update of an insider's beneficial ownership stake, common in the biotechnology or pharmaceutical industry for executives and directors. It does not provide information to assess broader industry trends or competitive positioning.
Legal Proceedings
- The Reporting Person, Jonathan H. Kaufman, has not been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors) during the last five years.
- The Reporting Person has not been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction that resulted in a judgment, decree, or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding of any violation with respect to such laws, during the last five years.
Stakeholder Impact
- Shareholders: Provides transparency regarding the ownership stake of a key executive and director, which can be a factor in assessing insider alignment.
Key Dates
| Date | Description |
|---|---|
| 2022-12-29 | Initial Statement on Schedule 13D filed by the Reporting Person. |
| 2023-06-21 | Amendment No. 1 to Schedule 13D filed. |
| 2024-03-06 | Amendment No. 2 to Schedule 13D filed. |
| 2024-03-15 | Amendment No. 3 to Schedule 13D filed. |
| 2024-03-19 | Amendment No. 4 to Schedule 13D filed. |
| 2024-05-06 | Amendment No. 5 to Schedule 13D filed. |
| 2024-10-17 | Amendment No. 6 to Schedule 13D filed. |
| 2024-12-27 | Amendment No. 7 to Schedule 13D filed. |
| 2025-01-03 | Amendment No. 8 to Schedule 13D filed. |
| 2025-01-17 | Amendment No. 9 to Schedule 13D filed. |
| 2025-01-23 | Amendment No. 10 to Schedule 13D filed. |
| 2025-01-30 | Amendment No. 11 to Schedule 13D filed. |
| 2025-02-06 | Date of event which requires filing of this statement (Amendment No. 12). |
| 2025-02-10 | Date of filing of Amendment No. 12. |
Keywords
Lipella Pharmaceuticals Inc., Jonathan H. Kaufman, Beneficial Ownership, Schedule 13D Amendment, Common Stock, Insider Ownership, SEC Filing, LPPM
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.